Northwestern Mutual Wealth Management Co. Has $167.29 Million Stock Holdings in Avanos Medical, Inc. $AVNS

Northwestern Mutual Wealth Management Co. boosted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 1,596,514.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,896,413 shares of the company’s stock after purchasing an additional 14,895,480 shares during the quarter. Northwestern Mutual Wealth Management Co. owned about 32.09% of Avanos Medical worth $167,287,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Thrivent Financial for Lutherans grew its holdings in Avanos Medical by 38.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 212,215 shares of the company’s stock worth $2,383,000 after purchasing an additional 58,451 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al grew its holdings in Avanos Medical by 19.0% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 58,804 shares of the company’s stock worth $660,000 after purchasing an additional 9,400 shares during the period. Versor Investments LP acquired a new stake in Avanos Medical in the fourth quarter worth $186,000. Inscription Capital LLC grew its holdings in Avanos Medical by 216.0% in the fourth quarter. Inscription Capital LLC now owns 36,990 shares of the company’s stock worth $415,000 after purchasing an additional 25,283 shares during the period. Finally, UBS Group AG grew its holdings in Avanos Medical by 7.9% in the fourth quarter. UBS Group AG now owns 415,107 shares of the company’s stock worth $4,662,000 after purchasing an additional 30,290 shares during the period. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings upgraded shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Finally, Zacks Research cut shares of Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, May 7th. Two analysts have rated the stock with a Sell rating, Based on data from MarketBeat, Avanos Medical presently has a consensus rating of “Sell”.

Avanos Medical Stock Up 0.1%

Avanos Medical stock opened at $24.73 on Friday. Avanos Medical, Inc. has a 1-year low of $9.30 and a 1-year high of $24.91. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -15.36 and a beta of 1.58. The firm’s fifty day moving average price is $18.53 and its two-hundred day moving average price is $14.55. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.16 by $0.06. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The firm had revenue of $182.20 million for the quarter, compared to analyst estimates of $170.00 million. During the same period last year, the firm earned $0.26 earnings per share. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts predict that Avanos Medical, Inc. will post 1.07 earnings per share for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.